Neurohumoral consequences of vasodilator therapy with hydralazine and nifedipine in severe congestive heart failure
Uri Elkayam(Icahn School of Medicine at Mount Sinai), Shahbudin H. Rahimtoola(Northwestern University), Willa A. Hsueh(The Ohio State University Wexner Medical Center), Lindalee Freidenberger, Laura Weber(University of Southern California), Arie Roth(Tel Aviv University)
Cited by 31
Related Papers
The hibernating myocardium
|American Heart Journal|1989|1.3k
Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial
|Journal of the American College of Cardiology|2000|1.1k
Current State of Knowledge on Aetiology, Diagnosis, Management, and Therapy of Peripartum Cardiomyopathy: A Position Statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy
|European Journal of Heart Failure|2010|1.1k
Guidelines for the Management of Patients With Valvular Heart Disease
|Circulation|1998|1k
Intravenous Nesiritide, a Natriuretic Peptide, in the Treatment of Decompensated Congestive Heart Failure
|New England Journal of Medicine|2000|908